Lavezzari G - Search Results

1

mGluR7 is a metaplastic switch controlling bidirectional plasticity of feedforward inhibition.

Pelkey KA, Lavezzari G, Racca C, Roche KW, McBain CJ. Pelkey KA, et al. Among authors: lavezzari g. Neuron. 2005 Apr 7;46(1):89-102. doi: 10.1016/j.neuron.2005.02.011. Neuron. 2005. PMID: 15820696

2

Constitutive endocytosis of the metabotropic glutamate receptor mGluR7 is clathrin-independent.

Lavezzari G, Roche KW. Lavezzari G, et al. Neuropharmacology. 2007 Jan;52(1):100-7. doi: 10.1016/j.neuropharm.2006.07.011. Epub 2006 Aug 7. Neuropharmacology. 2007. PMID: 16890965

3

Corequirement of PICK1 binding and PKC phosphorylation for stable surface expression of the metabotropic glutamate receptor mGluR7.

Suh YH, Pelkey KA, Lavezzari G, Roche PA, Huganir RL, McBain CJ, Roche KW. Suh YH, et al. Among authors: lavezzari g. Neuron. 2008 Jun 12;58(5):736-48. doi: 10.1016/j.neuron.2008.03.028. Neuron. 2008. PMID: 18549785 Free PMC article.

4

mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082.

Pelkey KA, Yuan X, Lavezzari G, Roche KW, McBain CJ. Pelkey KA, et al. Among authors: lavezzari g. Neuropharmacology. 2007 Jan;52(1):108-17. doi: 10.1016/j.neuropharm.2006.07.020. Epub 2006 Aug 17. Neuropharmacology. 2007. PMID: 16914173

5

Differential binding of the AP-2 adaptor complex and PSD-95 to the C-terminus of the NMDA receptor subunit NR2B regulates surface expression.

Lavezzari G, McCallum J, Lee R, Roche KW. Lavezzari G, et al. Neuropharmacology. 2003 Nov;45(6):729-37. doi: 10.1016/s0028-3908(03)00308-3. Neuropharmacology. 2003. PMID: 14529712

6

Subunit-specific regulation of NMDA receptor endocytosis.

Lavezzari G, McCallum J, Dewey CM, Roche KW. Lavezzari G, et al. J Neurosci. 2004 Jul 14;24(28):6383-91. doi: 10.1523/JNEUROSCI.1890-04.2004. J Neurosci. 2004. PMID: 15254094 Free PMC article.

7

Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays.

Lavezzari G, Lackner MR. Lavezzari G, et al. Methods Mol Biol. 2012;795:203-15. doi: 10.1007/978-1-61779-337-0_14. Methods Mol Biol. 2012. PMID: 21960225

8

What evidence do we need for biomarker qualification?

Leptak C, Menetski JP, Wagner JA, Aubrecht J, Brady L, Brumfield M, Chin WW, Hoffmann S, Kelloff G, Lavezzari G, Ranganathan R, Sauer JM, Sistare FD, Zabka T, Wholley D. Leptak C, et al. Among authors: lavezzari g. Sci Transl Med. 2017 Nov 22;9(417):eaal4599. doi: 10.1126/scitranslmed.aal4599. Sci Transl Med. 2017. PMID: 29167393 Review.

9

Industry perspectives on biomarker qualification.

Lavezzari G, Womack AW. Lavezzari G, et al. Clin Pharmacol Ther. 2016 Feb;99(2):208-13. doi: 10.1002/cpt.264. Epub 2015 Oct 22. Clin Pharmacol Ther. 2016. PMID: 26378777 Free PMC article. Review.

10

Advancing Value Assessment in the United States: A Multistakeholder Perspective.

Sorenson C, Lavezzari G, Daniel G, Burkholder R, Boutin M, Pezalla E, Sanders G, McClellan M. Sorenson C, et al. Among authors: lavezzari g. Value Health. 2017 Feb;20(2):299-307. doi: 10.1016/j.jval.2016.11.030. Value Health. 2017. PMID: 28237214 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results